Ivaltinostat is a novel oncology drug candidate engineered with advantages of excellent therapeutic effects, low side-effects, and immune balance inducement as a best-in-class molecular targeted inhibitor that disrupts the function of histone deacetylase (HDAC) which can cause cancer growth.
With the FDA’s orphan drug designation (ODD), CrystalGenomics will be eligible to be exempt from fees for applying for U.S. regulatory approval and 50 percent tax credit for clinical trial costs.
CrystalGenomics said it plans to expand indications of Ivaltinostat for different cancer types as monotherapy or in combination. It is preparing to conduct a phase 1/2a trial of the drug in combination with an immune checkpoint inhibitor in patients with liver cancer in the U.S.
In the U.S., 19,940 people were diagnosed with acute myeloid leukemia in 2020 alone and 11,180 people died from this disease, according to estimates out from the American Cancer Society. The AML treatment market is projected to be worth $950 million by 2024 in seven major countries.
The Kosdaq-listed stock closed Monday down 1.19 percent at 16,550 won ($15.06) after going as high as 17,300 won.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지
매일경제 주요 뉴스
해당 언론사로 연결됩니다.
- Samsung, LG to highlight pioneering screen tech at virtual CES 2021 - Pulse by Maeil Business News Korea
- Seoul shells out record high of $11 bn in unemployment benefit in 2020 - Pulse by Maeil Business News Korea
- BTS to open Samsung Galaxy S21 online unpacking Thursday - Pulse by Maeil Business News Korea
- GM Korea vows comeback with facility investment and new releases - Pulse by Maeil Business News Korea
- Retail ownership in Samsung Elec doubles, outweighs institutional holding - Pulse by Maeil Business News Korea
- ‘이병헌 협박女’ BJ 김시원, 6일 만에 별풍선 수익 ‘7억’
- 벼랑끝 화해…尹 "빨리 선거운동 하는게 중요" [영상]
- 모모랜드 아인, 파격적인 비키니..섹시美 폭발
- 윤석열 "아내 김건희, 대선 출마에 도장찍자고"
- `은밀한 뉴스룸` 세리 "코로나19 확진→미각·후각 사라져..폐렴까지 앓았다"